Angle PLC Angle & QIAGEN Poster
May 03 2018 - 02:00AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
03 May 2018
For immediate release 3 May 2018
ANGLE plc ("the Company")
ANGLE AND QIAGEN PRESENT POSTER AT LEADING CANCER CONFERENCE
DEMONSTRATING UTILITY OF ANGLE'S PARSORTIX SYSTEM IN CONJUNCTION
WITH QIAGEN'S ADNATEST ASSAY
First joint marketing material released under ANGLE and QIAGEN
logos
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to report that its co-marketing agreement with
QIAGEN(R) announced on 11 September 2017 is progressing well.
Work on combining ANGLE's Parsortix(TM) system to harvest
circulating tumor cells (CTCs) in prostate cancer with QIAGEN's
downstream AdnaTest gene expression analysis kit is being presented
today as a joint scientific poster at ISMRC 2018, the 11th
International Symposium on Minimal Residual Cancer in Montpellier,
France.
A joint marketing document has been prepared under both
companies' logos describing the combination of Parsortix and
AdnaTest and with particular reference to the measurement of AR-V7
in prostate cancer. Measurement of the expression of AR-V7 on CTCs
obtained from a blood test provides new insights into tumour
biology and has been found to correlate with the patient's expected
response, or lack of, to key drugs used in the treatment of
prostate cancer.
The joint marketing document is available here
https://angleplc.com/translational-research/mens-health/prostate-cancer/
and the poster here
https://angleplc.com/library/publications/
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"Partnering is a core part of ANGLE's strategy to secure
widespread adoption of the Parsortix system right across the
market, leveraging the customer base and distribution channels of
established players and today's news demonstrates the good progress
we have made in our collaboration with QIAGEN towards offering
combined solutions for the treatment of cancer."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Adrian Hargrave,
Simon Hicks, Kate Bannatyne
Corporate Broking - Alice Lane, Nikita
Jain +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig,
Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000
Evan Smith, Anne Troy (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called Ziplex(R) and is based on a patented flow
through array technology. It provides for highly multiplexed, rapid
and sensitive capture of targets from a wide variety of sample
types. A proprietary chemistry allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. These technologies can be combined to provide fully
automated, sample to answer results in both centralised laboratory
and point of use cartridge formats. It is ideal for measuring gene
expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
About QIAGEN www.qiagen.com
QIAGEN N.V., a Netherlands-based holding company, is the leading
global provider of Sample to Insight solutions that enable
customers to gain valuable molecular insights from samples
containing the building blocks of life. Our sample technologies
isolate and process DNA, RNA and proteins from blood, tissue and
other materials. Assay technologies make these biomolecules visible
and ready for analysis. Bioinformatics software and knowledge bases
interpret data to report relevant, actionable insights. Automation
solutions tie these together in seamless and cost-effective
workflows. QIAGEN provides solutions to more than 500,000 customers
around the world in Molecular Diagnostics (human healthcare),
Applied Testing (forensics, veterinary testing and food safety),
Pharma (pharma and biotech companies) and Academia (life sciences
research). As of June 30, 2017, QIAGEN employed approximately 4,600
people in over 35 locations worldwide. Further information can be
found at http://www.qiagen.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAATMPTMBMMBAP
(END) Dow Jones Newswires
May 03, 2018 02:00 ET (06:00 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2023 to Mar 2024